Abstract
Clinically nonfunctioning pituitary adenomas are one of the most common types of pituitary tumors. Unless they present with symptoms related to local mass effect, most tumors are detected incidentally when imaging studies are performed for other reasons. Although clinically nonfunctioning, most of these tumors have evidence, in vitro, of gonadotropin hormone or glycoprotein subunit production. The gonadotropins or their monomer submits rarely cause clinically identifiable effects. When these tumors present as macroadenomas, often with associated mass effect and hypopituitarism, primary therapy is neurosurgery. The role for medical therapy will be reviewed here.
Similar content being viewed by others
References
Katznelson L, Alexander JM, Bikkal HA, et al. Imbalanced follicle-stimulating hormone beta-subunit hormone biosynthesis in human pituitary adenomas. J Clin Endocrinol Metab 1992;74:1343.
Beckers A, Stevenaert A, Mashiter K, et al. Follicle-stimulating hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 1985;61:525.
Borges JL, Ridgway EC, Kovacs K, et al. Follicle-stimulating hormone-secreting pituitary tumor with concomitant elevation of serum alpha-subunit levels. J Clin Endocrinol Metab 1984;58:937.
Chapman AJ, MacFarlane IA, Shalet SM, et al. Discordant serum alpha-subunit and FSH concentrations in a woman with a pituitary tumour. Clin Endocrinol 1984;21:123.
Friend JN, Judge DM, Sherman BM, et al. FSH-secreting pituitary adenomas: Stimulation and suppression studies in two patients. J Clin Endocrinol Metab 1976;43:650.
Oppenheim DS, Kana AR, Sangha JS, et al. Prevalence of alpha-subunit hypersecretion in patients with pituitary tumors: Clinically nonfunctioning and somatotroph adenomas. J Clin Endocrinol Metab 1990;70:859.
Ridgway EC, Klibanski A, Ladenson PW, et al. Pure alpha-secreting pituitary adenomas. N Engl J Med 1981;304:1254.
Klibanski A, Deutsch PJ, Jameson JL, et al. Luteinizing hormone-secreting pituitary tumor: Biosynthetic characterization and clinical studies. J Clin Endocrinol Metab 1987;64:536.
Jameson JL, Klibanski A, Black PM, et al. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas. J Clin Invest 1987;80:1472.
Mashiter K, Adams E, Van-Noorden S. Secretion of LH, FSH, and PRL shown by cell culture and immunocytochemistry Shomali and Katznelson of human functionless pituitary adenomas. Clin Endocrinol 1981;15:103.
Yamada S, Asa SL, Kovacs K, et al. Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay. J Clin Endocrinol Metab 1989;68:73.
Esiri MM, Adams CB, Burke C, Underdown R. Pituitary adenomas: Immunohistology and ultrastructural analysis of 118 tumors. Acta Neuropathol 1983;62(1/2):1–14.
Cotran RS, Kumar V, Collins T (eds.). Robbins Pathologic Basis of Disease, 6th ed. Philadelphia: W.B. Saunders Company, 1998.
Asa SI, Bamberger AM, Cao B, Wong M, Parker KI, Ezzat S. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab 1996;81:2165–2170.
Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86(1):336–340.
Kumar TR, Graham KE, Asa SL, Low MJ. Simian virus 40 T antigen-induced gonadotroph adenomas: A model of human null cell adenomas. Endocrinology 1998;139:3342–3351.
Gittoes NJL. Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. Journal of Endocrinology 1998;157:177–186.
Zhao D, Tomono Y, Tsuboi K, Nose T. Immunohistochemical and ultrastructural study of clinically nonfunctioning pituitary adenomas. Neurol Med Chir 2000;40:453–457.
Breen P, Flickinger JC, Kondziolka D, Martinez AJ. Radiotherapy for nonfunctional pituitary adenoma: Analysis of long-term tumor control. J Neurosurg 1998;89:933–938.
Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W. Silent corticotropic adenomas of the human pituitary gland: A histologic, immunocytologic, and ultrastructural study. Am J Pathol 1980;98(3):617–638.
Shomali ME, Hussein M. Cushing's syndrome: From patients to proteins. Eur J Endocrinol 2000;143:313–315.
Warnet A, Porsova-Dutoit I, Lahlou N, Seret-Begue D, Lajeunie E, Chanson P, Woimant F, Lot G, Guillauseau PJ, Roger M. Glycoprotein hormone-alpha-subunit secretion in prolactinomas and in non-functioning adenomas: Relation with the tumour size. Clinical Endocrinology 1994;41:177–184.
Cooper ME, Murray RML, Kalnins R, Woodward J, Jerums G. The development of Cushing's syndrome from a previously silent pituitary tumour. Aust NZ J Med 1987;17:249–251.
Vaughan NJ, Laroche CM, Goodman I, et al. Pituitary Cushing's disease arision from a previously non-functional corticotrophic chromophobe adenoma. Clinical Endocrinology 1985;22:147–153.
Roncaroli F, Scheithauer BW, Cenacchi G, Horvath E, Kovacs Klloyd RV, Abell-Aleff P, Santi M, Yates AJ. "Spindle cell oncocytoma" of the adenohypophysis: A tumor of folliculostellate cells? Am J Surg Pathol 2002;26:1048–1055.
Schaller B, Kirsch E, Tolnay M, Mindermann T. Symptomatic granular cell tumor of the pituitary gland: Case report and review of the literature. Neurosurgery 1998;42:166–171.
Arafah BM, Nasrallah MP. Pituitary tumors: Pathophysiology, clinical manifestations, and management. Endocrine-Related Cancer 2001;8:287–305.
Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1986;62:1173.
Harris PE, Afshar F, Coates P, et al. The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary tumours. Q J Med, New Series 1989;71:417.
Heshmati HM, Turpin G, Kujas M, Lam X, Van Effenterre R, Racadot J, de Gennes JL. The immunocytochemical heterogeneity of silent pituitary adenomas. Acta Endocrinologica 1988;118:533–537.
Ho DM, Hsu CY, Ting LT, Chiang H. The clinicopathological characteristics of gonadotroph cell adenoma: A study of 118 cases. Hum Pathol 1997;28(8):905–911.
Black PM, Hsu DW, Klibanski A, Kliman B, Jameson L, Ridgway EC, Hedley-Whyte T, Zervas NT. Hormone production in clinically nonfunctioning pituitary adenomas. J Neurosurg 1987;66:244–250.
Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann Intern Med 1994;120(10):817–820.
Aron DC, Howlett TA. Pituitary incidentalomas. Endoc Metab Clin North Am 2000;29(1):205–221.
Molitch ME. Pituitary incidentalomas. Endoc Metab Clin North Am 1997;26(4):725–740.
King JT Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: A cost-effectiveness analysis. J Clin Endocrinol Metab 1997;82(11):3625–3632.
Heseltine D, White MC, Kendall-Taylor P, De Kretser DM, Kelly W. Testicular enlargement and elevated serum inhibin concentrations occur in patients with pituitary macroadenomas secreting follicle stimulating hormone. Clin Endocrinol 1989;31(4):411–423.
Tashiro H, Katabuchi H, Ohtake H, Yoshioka A, Matsumura S, Suenaga Y, Nagamura Y, Matsuura K, Okamura H. An immunohistochemical and ultrastructural study of a follicle-timulating hormone-secreting gonadotroph adenoma occurring in a 10-year-old girl. Med Electron Microsc 2000;33:25–31.
Shimon I, Rubinek T, Bar-Hava I, Nass D, Hadani M, Amsterdam A, Harel G. Ovarian hyperstimulation without elevated serum estradiol associated with pure follicle-stimulating hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 2001;86:3635–3640.
Balagura S, Frantz A, Housepian E, et al. The specificity of serum prolactin as a diagnostic indicator of pituitary adenoma. J Neurosurg 1979;51:42.
Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary adenomas. Trends Endocrinol Metab 1992;3:41.
Edmonds M, Molitch M, Pierce G, et al. Secretion of alpha subunits of luteinizing hormone (LH) by the anterior pituitary. J Clin Endocrinol Metab 1975;41:551.
Kourides, I, Weintraub B, Rosen S, et al. Secretion of alpha subunit of glycoprotein hormones by pituitary adenomas. J Clin Endocrinol Metab 1976;43:97.
MacFarlane IA, Beardwell CG, Shalet SM, et al. Glycoprotein hormone {alpha} subunit secretion by pituitary adenomas: Influence of external irradiation. Clin Endocrinol 1980;13:215.
Demura R, Jibiki K, Kubo O, et al. The significance of alphasubunit as a tumor marker for gonadotropin-producing pituitary adenomas. J Clin Endocrinol Metab 1986;63:564.
Landolt AM, Heitz PU. Alpha-subunit-producing pituitary adenomas. Immunocytochemical and ultrastructural studies. Virchows Arch Pathol Anat Histopathol 1986;409:417.
Ishibashi M, Yamaji T, Takaku F, et al. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors. J Clin Endocrinol Metab 1987;64:1187.
Daneshdoost L, Gennarelli TA, Bashey HM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta-subunit response to thyrotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:1352.
Gil-del-Alamo P, Pettersson KSI, Saccomanni K, et al. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with nonfunctioning pituitary adenoma. Clin Endocrinol 1994;41:661.
Snyder PJ, Sterling FH. Hypersecretion of LH and FSH by a pituitary adenoma. J Clin Endocrinol Metab 1976;42:544.
White MC, Daniels M, Newland P, et al. LH and FSH secretion and responses to GnRH and TRH in patients with clinically functionless pituitary adenomas. Clin Endocrinol 1990;32:681.
Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med 1995;155:181.
Reincke M, Allolio B, SaegerW, et al. The 'incidentaloma' of the pituitary gland: Is neurosurgery required? J Amer Med Assoc 1990;263:2772.
Black PM, Zervas NT, Candia G. Management of large pituitary adenomas by transsphenoidal surgery. Surg Neurol 1988;29:443.
Ciric I, Mikhael M, Stafford T, et al. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J Neurosurg 1983;59:395.
Boelaert K, Gittoes Neil JL. Radiotherapy for non-functioning pituitary adenomas. Europ J Endocrinol 2001;144:569–575.
Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, Stewart PM. Radiotherapy for non-function pituitary tumours. Clin Endocrinol 1998;48(3):331–337.
Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986;81:457.
Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989;70:145.
Ikuyama S, Nawata H, Kato K, et al. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985;61:666.
Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumor subclasses. J Clin Endocrinol Metab 1987;65:65.
Faglia G, Bazzoni N, Spada A, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090). J Clin Endocrinol Metab 1991;73:850.
Klibanski A, Alexander JM, Bikkal HA, et al. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab 1991;73:1248.
Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999;141(4):396–408.
Merola B, Colao A, Ferone D, et al. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1993;40:149.
Muhr C, Bergstrom M, Lundberg PO, et al. Positron emission topography for the in vivo characterization and follow-up of treatment in pituitary adenomas. In Landolt AM, Heitz PU, Zapf J, et al. (eds.). Advances in Pituitary Adenoma Research. Oxford: Pergamon Press, 1988:163.
de-Bruin TW, Kwekkeboom DJ, Vant-Verlaat JW, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992;75:1310.
Gasperi M, Petrini L, Pilosu R, et al. Octreotide treatment does not affect the size of most nonfunctioning pituitary adenomas. J Endocrinol Invest 1993;16:541.
Katznelson L, Oppenheim DS, Coughlin JF, et al. Chronic somatostatin analog administration in patients with alphasubunit-secreting pituitary tumors. J Clin Endocrinol Metab 1992;75:1318.
Warnet A, Harris AG, Renard E, et al. Aprospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas: French Multicenter Octreotide Study Group. Neurosurg 1997;41:786.
Plockinger U, Bader M, Hopfenmuller W, et al. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 1997;136:369.
Broson-Chazot F, Houzard C, Ajzenberg C, et al. Somatostatin receptor imaging in somatotroph and nonfunctioning pituitary adenomas: Correlation with hormonal and visual responses to octreotide. Clin Endocrinol 1997;47:589.
Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000;62(Suppl 1):27–32.
Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001;12(Suppl 2):531–536.
Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997;100:2386–2392.
Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J, Jorgensen JO. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 2001;24:430–437.
Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996;10(12):1688–1696.
Bevan JS, Burke CW. Nonfunctioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol 1986;25:561.
Kwekkeboom DJ, Hofland LJ, van Koetsveld PM, et al. Bromocriptine increasingly suppresses the in vitro gonadotropin and {alpha}-subunit release from pituitary adenomas during long term culture. J Clin Endocrin Metab 1990;71:718.
Klibanski A, Shupnik MA, Bikkal HA, et al. Dopaminergic regulation of alpha-subunit secretion and messenger ribonucleic acid levels in alpha-secreting pituitary tumors. J Clin Endocrinol Metab 1988;66:96.
Vance ML, Ridgway EC, Thorner MO. Follicle-stimulating hormone-and alpha-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab 1985;61:580.
Barrow DL, Tindall GT, Kovacs K, et al. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg 1984;60:1.
D'Emden MC, Harrison LC: Rapid improvement in visual field defects following bromocriptine treatment of patients with non-functioning pituitary adenomas. Clin Endocrinol 1986;25:697.
Grossman A, Ross R, Charlesworth M, et al. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clin Endocrinol 1985;22:679.
van-Schaardenburg D, Roelfsema F, van-Seters AP, et al. Bromocriptine therapy for non-functioning pituitary adenoma. Clin Endocrinol 1989;30:475.
Verde G, Oppizzi G, Chiodini PG, et al. Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas. J Endocrinol Invest 1985;8:113.
Wollesen F, Andersen T, Karle A. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann Intern Med 1982;96:281.
Giusti M, Bocca L, Florio T, Foppiani L, Corsaro A, Auriati L, Spaziante R, Schettini G, Giordano G. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest 2000;23:463–466.
Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R, Paschke R. Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 2001;4:173–178.
Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: Predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol 2000;52(4):437–445.
Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH, Hagen C. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol 2001;54(1):23–30.
Kwekkeboom DJ, de Jong FH, Lamberts SW. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: Relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone, and bromocriptine. J Clin Endocrinol Metab 1989;68(6):1128–1135.
Chanson P, Lahlou N, Warnet A, Roger M, Sassolas G, Lubetzi J, Schaison G, Bouchard P. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas. J Endocrinol Invest 1994;17(2):91–98.
Klibanski A, Jameson JL, Biller BM, Crowley WF Jr, Zervas NT, Rivier J, Vale WW, Bikkal H. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J Clin Endocrinol Metab 1989;68(1):81–86.
Colombo P, Ambrosi B, Saccomanno K, Bassetti M, Cortelazzi D, Faglia G. Effects of long-term treatment with the gonadotropin-releasing hormone analog nafarelin in patients in patients with non-functioning pituitary adenomas. Eur J Endocrinol 1994;130:339–345.
McGrath GA, Goncalves RJ, Udupa JK, Grossman RI, Pavlou SN, Molitch ME, Rivier J, Vale WW, Snyder PJ. New technique for quantitation of pituitary adenoma size: Use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 1993;76(5):1363–1368.
Castro MG, Southgate T, Lowenstein PR. Molecular therapy in a model neuroendocrine disease: Developing clinical gene therapy for pituitary tumours. Trends Endocrinol Metab 2001;12(2):58–64.
Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study. Pathol Endocr 1995;6(2):115–124.
Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001;438(6):595–602.
de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses. Curr Opin Oncol 2002;14:53–57.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shomali, M.E., Katznelson, L. Medical Therapy of Gonadotropin-Producing and Nonfunctioning Pituitary Adenomas. Pituitary 5, 89–98 (2002). https://doi.org/10.1023/A:1022312530900
Issue Date:
DOI: https://doi.org/10.1023/A:1022312530900